SecBot SecBot
8-K ·Filed Jun 24, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001493152-26-029918
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The 17.7% dilution is material for a $402M market cap biotech. Monitor for the resale registration statement filing (due ~Sep 15, 2026) and any subsequent selling by investors. The stock may face near-term pressure from the overhang of registered shares.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.26
T+0 close · Jun 24, 2026 · via day close
Latest settled
+8.90%
T+60 · $3.55
Vs SPY
+5.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $3.26entry
  2. T+1 · 5mo ago +4.60%α +5.32% · $3.41
  3. T+5 · 5mo ago −9.82%α −11.38% · $2.94
  4. T+20 · 4mo ago −15.03%α −15.56% · $2.77
  5. T+60 · 8w ago +8.90%α +5.17% · $3.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics raised approximately $12 million through a private placement of 20 million shares at $0.60 per share to non-U.S. accredited investors, representing ~17.7% dilution relative to the ~113.2 million shares outstanding. Proceeds are earmarked for working capital, clinical development, and general corporate purposes, with registration rights granted for resale.

Key Financial Metrics

Offering Size
$12.0M
Dilution
17.7%

Key Facts

  • 20,000,000 shares sold at $0.60/share for ~$12M gross proceeds
  • Dilution of ~17.7% based on ~113.2M shares outstanding pre-offering
  • Shares sold to non-U.S. accredited investors under Regulation S
  • Company granted registration rights for resale; filing due within 90 days of closing
  • Use of proceeds: working capital, clinical development, regulatory activities, general corporate purposes

Financial Impact

~$12M gross proceeds with ~17.7% dilution; no commissions paid

dilutionshare count

Risk Factors

  • Dilution overhang from 20M new shares eligible for resale under registration rights
  • Potential downward price pressure as investors may sell into the market
  • Clinical-stage biotech with no revenue; cash burn may require further financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-029918
Document: form8-k.htm0001493152-26-029918
Document: 0001493152-26-029918-index-headers.html0001493152-26-029918
Document: 0001493152-26-029918-index.html0001493152-26-029918
Document: 0001493152-26-029918.txt0001493152-26-029918

Track record

20 reports on INDP

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026